Skip to content
type1.science
N/A (device / behavioral)CompletedNCT07325461

Extended-wear infusion set options at home

What this study tests

Feasibility study of extended-wear insulin infusion set options during home use in T1D.

Editorial review: .

Registry checked: 2026-09-17. Registry’s own update: 2026-08-31.

Source dates appear in the references where available; this record has no dated citation metadata.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?
Adults 18–80 with T1D for at least 12 months using a Tandem pump and Dexcom CGM, HbA1c below 9% and BMI18–35. Willingness to wear study sets up to 7 days and monitor blood ketones is required. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results
No results posted yet.Read the result sources and their limitations →
Important harms
Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval
Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?
Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

  • 7 Day Survival of Infusion Set for Primary Outcome Measure

The full picture

This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.

Sources

  1. [1]